DJIA 16,912.11 -70.48 -0.42%
NASDAQ 4,442.70 -2.21 -0.05%
S&P 500 1,969.95 -8.96 -0.45%
market minute promo

Ophthotec (NASDAQ: OPHT)

40.51 1.23 (3.13%)

Quote as of


company name or ticker

Recent Quotes

OPHT $40.51 3.13%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $39.31
Previous Close $39.28
Daily Range $39.30 - $40.77
52-Week Range $22.61 - $47.99
Market Cap $1.4B
P/E Ratio -14.82
Dividend (Yield) $0.00 (0.0%)
Volume 125,738
Average Daily Volume 295,632
Current FY EPS -$2.67

Sector

Industry

Ophthotec (OPHT) Description

Ophthotech Corp is a biopharmaceutical company specializing in the development of novel therapeutics to treat diseases of the back of the eye with a focus on developing therapeutics for age-related macular degeneration. Website: http://www.ophthotechinc.com/

News & Commentary

Benzinga's Top Initiations

Ohr Pharmaceutical: Questionable Analyst Activity

Phase II Calamity Dooms Ohr's Eye Drops

Why Ophthotech (OPHT) Could Be Positioned for a Surge? - Tale of the Tape

Why Ophthotech (OPHT) Could Be Positioned for a Surge? - Tale of the Tape

Isis Shines, PTC Therapeutics Soars - Analyst Blog

Ophthotech (OPHT) Jumps: Stock Rises 24.5% - Tale of the Tape

Why Ophthotech (OPHT) Stock Is Surging Today

Benzinga's Volume Movers

UPDATE: Ophthotech Announces Has Entered Into Ex-US Licensing, Commercialization Deal with Novartis,

UPDATE: Ophthotech Announces Has Entered Into Ex-US Licensing, Commercialization Deal with Novartis, Will Potentially Get Upfront Payment of $200M, Receive Over $1B

Ophthotech's (OPHT) CEO David Guyer on Q1 2014 Results - Earnings Call Transcript

See More OPHT News...